Future Outlook of the Ovarian Cancer Treatment Landscape
Leslie Randall, MD, MAS, offers closing thoughts on the future trajectory of ovarian cancer treatment.
Updated FDA Approvals for PARP Inhibitors in Ovarian Cancer
An expert gynecologic oncologist comments on recent revisions to FDA-approved indications for PARP inhibitors in the treatment of ovarian cancer.
Recent Long-Term Data on PARP Inhibitors in Ovarian Cancer
Leslie Randall, MD, MAS, reviews recent long-term data on PARP inhibitors in the treatment of ovarian cancer.
Managing Adverse Events from PARP Inhibitors in Ovarian Cancer
Clinical insights on how to manage adverse events for patients with ovarian cancer who are receiving PARP inhibitors.
Treatment Considerations for PARP Inhibitors in Ovarian Cancer
An expert on ovarian cancer discusses factors that influence PARP inhibitor selection, when to initiate maintenance therapy, and how to counsel patients on PARP inhibitors.
Maintenance Therapy Treatment Landscape for BRCA-Mutated Advanced Ovarian Cancer
Leslie Randall, MD, MAS, reviews the available treatment options for BRCA-mutated advanced ovarian cancer.
Guideline Recommendations for Molecular Testing in Ovarian Cancer
An overview of guideline recommendations for molecular testing in ovarian cancer.
Patient Profile: A 55-Year-Old with BRCA-Mutated Ovarian Cancer
Leslie Randall, MD, MAS, presents the case of a 55-year-old woman with BRCA-mutated ovarian cancer and provides her initial impressions.
Ovarian Cancer: Future Directions in Care
Closing out her discussion on ovarian cancer, Leslie Randall, MD, shares closing advice for community physicians on optimal treatment strategies.
Recurrent Ovarian Cancer: Treatment Options and Maintenance Therapy
Leslie Randall, MD, considers the possibility of relapse in ovarian cancer and reviews treatment options available at recurrence.
PARP Inhibition in Ovarian Cancer: Safety Profiles and Dose Adjustment
Focused discussion on the safety profiles of PARP inhibitors in ovarian cancer and how these can be mitigated with proper dose management.
Considering PARP Inhibitor Maintenance in Ovarian Cancer
Shared insight on the selection of PARP inhibitors for maintenance therapy in ovarian cancer with deference to patient and disease factors.
Maintenance Therapy Selection and Use in Ovarian Cancer
A broad look at maintenance therapy selection and its use in ovarian cancer to improve patient outcomes.
Ovarian Cancer Patient Case: Prognosis and Molecular Testing
Expert Leslie Randall, MD, discusses the case of a 71-year-old woman who is diagnosed with ovarian cancer. Dr. Randall reviews data with PARP inhibitors and rationale for use of maintenance therapy in patients with platinum-sensitive disease.
Olaparib Maintenance Therapy in Ovarian Cancer
Leslie M. Randall, MD, associate professor of Gynecology/Oncology, University of California Irvine, discusses the use of olaparib as maintenance therapy in the treatment of patients with ovarian cancer.
2 Clarke Drive Cranbury, NJ 08512